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Background: Although intuitively sound, the efficacy and safety of enoxaparin bridging (EB) in patients with mechanical valves (MV), compared to 
withholding warfarin without EB, has yet to be determined. We sought to clarify this issue by analyzing our ten-year experience with periprocedural 
anticoagulation management in this patient group.
Methods: Of 2,687 patients on warfarin screened, 513 patients had warfarin stopped for 727 separate invasive procedures. Of these procedures, 
115 were performed in patients who were taking warfarin for mechanical valve thromboprophylaxis. For 80 of these procedures, patients were 
bridged with enoxaparin and for the remaining 35 procedures, warfarin was withheld without EB. The decision to bridge a patient or not was solely at 
the discretion of the managing physician, hence the observational nature of this study. We compared adverse periprocedural events in the bridged 
versus non-bridged groups using a two-tailed Chi Square test.
Results: There occurred 20 total periprocedural complications, 16 hemorrhagic and 4 thromboembolic in nature. In addition, 7 complications were 
classified as major in severity and 13 as minor. The comparison of the complications between the bridged and non-bridged groups is shown in Table.
Conclusions: In this retrospective study, EB in patients with MV, compared to stopping warfarin without EB, appeared to possibly lessen major 
thromboembolic complications and was associated with a higher incidence of minor periprocedural bleeding.
Periprocedural Complications in Bridged versus Non-Bridged Groups
Non-bridged Procedures (n=35) Bridged Procedures (n=80) P value
Total Complications (n=20) 3 (8.6%) 17 (21.3%) 0.099
Hemorrhagic Complications (n=16) 0 (0%) 16 (20%) 0.004
Thromboembolic Complications (n=4) 3 (8.6%) 1 (1.3%) 0.049
Major Complications (n=7) 3 (8.6%) 4 (5%) 0.461
Major Hemorrhagic (n=3) 0 (0%) 3 (3.8%) 0.246
Major Thromboembolic (n=4) 3 (8.6%) 1 (1.3%) 0.049
Minor Complications (n=13) 0 (0%) 13 (16.3%) 0.011
Minor Hemorrhagic (n=13) 0 (0%) 13 (16.3%) 0.011
Minor Hemorrhagic (n=0) 0 (0%) 0 (0%) NA
